

Index

- absorption of alcohol, 25
 abstinence. *see also*
 non-abstinence treatment
 cerebellar degeneration, 79
 during conception and pregnancy, 85
 drug use with, 112
 inability to sustain, 107
 medical problems during, 85
 other treatment outcomes, 3
 psychiatric disorders, 89
 reinstatement after, 19, 162
 acamprosate, 198, 201, 204–205, 208
 accidental injury, 56, 77
 acute alcohol intoxication and coma, 65–66
 acute myopathy, 74–75
 acute pancreatitis, 64, 71
 acute pharmacological effects, 28–29
 acute tolerance, 16
 adjustment during childhood, 156
 adolescents and polydrug use, 115–116
 adrenocorticotrophic hormone (ACTH), 73
 adult respiratory distress syndrome (ARDS), 76
 advance judgment for specialty care, 147
 adverse side-effect profile, 45
 advice in BMI intervention, 149
 age of legal purchase, 38
 aggressiveness concerns, 58
 aggressive/violent patients, 249–251, 250*t*
 alcohol, as drug
 absorption/distribution of, 25
 acute pharmacological effects, 28–29
 blood alcohol concentrations, 23–25
 brain circuits, 30–31
 chemical structure, 23, 24
 excretion and metabolism, 25–27
 future directions, 35–36
 neuroimaging, 29–30
 overview, 2, 23
 pharmacology, 23, 24*t*, 31
 tolerance and withdrawal, 32, 34–35
 alcohol by volume (ABV), 25
 alcohol dehydrogenase (ADH), 32, 26–27, 44, 70
 alcohol dependence (syndrome)
 absence of withdrawal symptoms, 19–20
 binge drinking and, 64
 clinical genesis of, 13
 defined, 8
 dependence concept, 20–21
 elements of, 13–17
 evidence of, 160–162
 importance of understanding, 20–21
 introduction, 1
 overview, 10–13, 14*t*
 questionnaires for measuring, 162
 reinstatement after abstinence, 162
 relapsing-remitting nature of, 190
 reward system in, 30, 31–33
 severe alcohol dependence, 5, 19
 stress and, 41, 53, 103
 time element of, 20
 Alcohol Dependence Scale, 162
 alcohol detoxification, 121, 122
 alcoholic ‘dementia,’ 76, 81
 alcoholic gastritis, 64
 alcoholic hallucinosis, 92, 95, 245
 alcoholic ketoacidosis, 73
 alcoholic polyneuropathy, 64
 Alcoholics Anonymous (AA)
 activities, 216–218
 change processes, 220–221
 controlled drinking controversy, 234
 cross talk, defined, 217
 effectiveness of, 224
 fellowship influence, 222
 impact of, 134, 172
 long-term attendee, 253
 non-religious nature of, 228
 overview, 3, 215–216
 professional affiliation of, 222–224
 rebellious patients, 248
 sponsorship in, 218
 twelve-step facilitation therapy, 196–197, 220*t*, 224–225
 the Washingtonians, 219–220
 alcohol-induced disorders, 92–95
 alcohol-induced psychotic disorder, 95–96
 alcoholism, 1, 20
 Alcohol Problems Questionnaire (APQ), 163
 alcohol-related brain damage (ARBD), 79, 82–83, 97–99
 alcohol use disorder (AUD), 9–10, 11–12*t*, 104
 Alcohol Use Disorders Identification Test (AUDIT), 144–145
 alcohol withdrawal. *see* withdrawal states/symptoms
 aldehyde dehydrogenase (ALDH), 44, 66, 68, 199
 alienation feelings, 116
 alternative medications during withdrawal, 175
 Alzheimer’s disease, 27
 American Institute for Cancer Research, 66
 American Medical Association, 200
 amnesia of Korsakoff’s syndrome, 81
 amnesic episodes. *see* blackouts
 amphetamine use, 113, 119, 125

Cambridge University Press

978-1-107-51952-7 - Edwards' Treatment of Drinking Problems: A Guide for the Helping Professions

Sixth Edition Keith Humphreys and Anne Lingford-Hughes

Index

[More information](#)

- anaemia, 76
 anorexia nervosa, 109
 anterior cingulate, 31
 anticonvulsant medication, 173, 174, 177
 antidepressants, 47, 78, 201
 antiretroviral medication effectiveness, 74
 anti-social behaviour, 56
 anti-social personality disorder, 90
 anxiety disorders, 89, 104–105, 207–208
 arrhythmias, 67
 assertiveness training, 193
 assessment of patients
 background history, 155
 case formulation and treatment planning, 166–167
 drinking history, 157–160
 essential process of, 167
 evidence of dependence, 160–162
 evidence of drinking consequences, 162–163
 family history, 155–156
 15-minute assessment, 165
 help-seeking by patients, 164–165
 history-taking, 153–154
 introduction, 2
 overview, 153
 with partner/significant other, 165–166
 personal history, 156
 physical examination and investigation, 165
 previous illnesses, 157
 setting tone for, 154–155
 specialist treatment, 191
 standard diagnostic systems, 162
 t-test origin, 163–164
 atrial fibrillation, 67
 atrial tachyarrhythmia, 69
 at-risk persons, screening, 140
 attention deficit hyperactivity disorder (ADHD), 107–108
 auditory hallucinations, 95
 Australian National Health and Research Council, 8
 autoimmunity, 74
 baclofen, 206
 beer consumption, 40, 73
 behavioural changes/disorders, 28, 50, 62, 64
 behavioural contracts, 195
 behavioural couples therapy (BCT), 195–196
 behavioural self-control training (BSCT), 194–195
 behavioural treatment protocols, 239
 benefit of drinking, patient perception, 149
 benzodiazepine-alcohol-opioid overdoses, 121
 benzodiazepine receptors, 34
 benzodiazepine use
 abstinence with, 112
 alcohol and, 121–122, 122*t*
 chlordiazepoxide, 121, 173
 cross-tolerance, 16
 dependence on, 180–181
 diazepam, 121, 173
 factors in, 113
 in withdrawal, 173–174, 176–177, 179
 binge drinking
 alcohol dependence syndrome and, 64
 defined, 9
 fetal alcohol spectrum disorders, 85
 nicotine use and, 117
 non-medicinal prescription drug use, 123
 parental drinking and, 56
 social factors, 51
 unconsciousness from, 65–66
 binge eating, 109
 biological factors and drinking problems
 epigenetics, 45
 genetics, 43–44
 metabolization of alcohol, 25–27, 39, 44
 neurobiological vulnerabilities, 45–46
 neurotransmitter pathways and treatment responses, 44–45
 overview, 42
 bipolar disorder, 103–104, 208
 blackouts (amnesic episodes), 96–97
 blood alcohol
 concentrations (BAC)
 accidents and trauma, 77
 breathalyser for measuring, 16, 25
 complexity of, 23–25
 dependence syndrome, 16
 gender differences, 25, 70
 laboratory tests, 143–144
 respiratory depression and death, 66
 withdrawal and, 175
 “blood-oxygen-level-dependent” (BOLD), 29
 body temperature, 28
 bone density, 75
 borderline personality traits, 107
 boredom and drinking, 6
 brain circuits, 30–31
 brain damage. *see* alcohol-related brain damage
 brain plasticity, 44
 breast cancer, 66
 breathalyser, 16, 25, 145
 brief motivational intervention (BMI), 148–149, 150*t*
 British Medical Association Board of Science, 66
 British Psychiatric Morbidity Survey, 91
 bruising symptoms, 140
 Buddhism, 229
 bulimia nervosa, 109
 buprenorphine treatment, 121
 bupropion treatment, 118
 business drinking, 5
 B-vitamin deficiency, 83
 CAGE questionnaire, 145
 cancer, 61, 66
 cannabinoid (CB1) receptors, 31
 cannabis, 112, 113, 114, 115, 119–120, 123
 carbohydrate-deficient (desialylated) transferrin (CDT), 143
 carbon dioxide bubbles, 25
 cardiomyopathy, 68–69
 ‘cardio-protective’ effect, 68
 cardiovascular disease, 28, 66
 case-finding and intervention, 2
 case formulation in assessments, 166–167
 case notes in assessments, 154

Cambridge University Press

978-1-107-51952-7 - Edwards' Treatment of Drinking Problems: A Guide for the Helping Professions

Sixth Edition Keith Humphreys and Anne Lingford-Hughes

Index

[More information](#)

- CDT lab test, 145
- central nervous system (CNS), 16, 28–29
- central pontine myelinolysis, 83
- cerebellar degeneration, 79
- chemical structure of alcohol, 23, 24
- children and family-related drinking problems. *see also* family-related drinking problems
- accidental injury of children, 56
- adjustment during childhood, 156
- education during childhood, 156
- parental drinking problems, 55–57, 56*t*
- physical abuse in childhood, 106
- risk to children, 56*t*, 55–57, 156
- sexual abuse of children, 56, 106
- chlordiazepoxide, 121, 173, 180
- chloride ions, 34
- Christianity, 228, 230, 231
- chronic back pain, 38
- chronic myopathy, 75
- chronic pancreatitis, 64, 71–72, 115
- chronic tolerance, 16
- cigarette smoking
- alcohol use and, 70, 76, 114
- chronic pancreatitis and, 71
- nicotine and alcohol, 117–118
- schizophrenia and, 108
- cirrhosis of liver, 61, 64, 69–71
- CIWA-Ar scale, 95
- Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA), 174
- club drugs, 123
- cocaethylene metabolite, 119
- cocaine use
- adolescent use, 116, 125
- alcohol impact on, 112, 113, 115, 118–119
- cocaethylene metabolite, 119
- Cochrane Collaboration
- review, 224
- codeine, 115
- coffee consumption, 70
- cognitive behavioural therapy (CBT)
- anxiety disorder, 105
- assessment and, 167
- depression, 102
- in specialized treatment, 193
- cognitive impairment, 79, 82–83, 97–99, 116
- Collaborative Study on the Genetics of Alcoholism (COGA), 43
- colorectal cancer, 66
- coma, 65–66, 179
- COMBINE studies, 202, 204, 205
- community detoxification, 134, 171
- community reinforcement and family training (CRAFT), 196
- community reinforcement approach (CRA), 194
- co-morbidity
- aetiology of, 89
- in assessments, 165
- depression, 99–101, 207
- gender differences, 90
- pharmacotherapeutic strategies with, 198, 207
- prevalence rates of, 89
- psychiatric disorders, 99
- Comprehensive International Diagnostic Interview (CIDI), 153
- compulsory admission, 178
- conduct disorder, 90, 156
- confabulation, 80
- contingency management, 194
- controlled drinking
- controversy, 234
- convergent functional genomics, 44
- co-occurring addictive/psychiatric disorders, 236
- coping and social skills training, 193–194
- coronary heart disease, 68
- corticotrophin-releasing hormone (CRHR1), 45
- crack cocaine, 112, 119
- craving experiences, 19
- crime and family-related drinking problems, 58–59
- criminal justice setting, 137
- cross-tolerance, 16
- CT scanning, 82
- cue exposure in specialist treatment, 195
- cue-reactivity studies, 30
- cyclothymia, 104
- CYP2E1 (cytochrome P450 2E1), 27
- daily intake totals, 160
- Danshukai organization, 216
- degree of dependence, 234
- delirium, 93
- delirium tremens (DTs)
- aetiology and course of, 92–93, 94
- complications, 178–179
- decreased magnesium levels, 179
- diagnostic confusion over, 95
- heightened suggestibility, 94
- introduction, 17
- transient hallucinatory experience, 92
- treatment of, 177–179, 178*t*, 244
- withdrawal and, 94, 169, 171, 177–179
- delta-tetrahydrocannabinol (THC), 120
- dementia, 74, 76, 81, 98, 140
- Department of Health (UK), 6
- Department of Veterans Affairs (VA) Cooperative Studies Program (US), 200
- dependence concept, 20–21
- depression
- anxiety with depression, 104–105
- cognitive behavioural therapy and, 102
- co-morbidity of, 99–101, 207
- depressive disorder, 62
- diagnostic question, importance, 102–103
- major depressive disorder, 101, 102, 106
- marital disharmony, 49–50
- neurotic depression, 100
- overview, 38, 47
- pharmacotherapy, 99–101, 207
- relationship between, 101–102
- detoxification
- alcohol detoxification, 121, 122
- community detoxification, 134, 171

Cambridge University Press

978-1-107-51952-7 - Edwards' Treatment of Drinking Problems: A Guide for the Helping Professions

Sixth Edition Keith Humphreys and Anne Lingford-Hughes

Index

[More information](#)

260

Index

- detoxification (cont.)
 in-patient detoxification
 checklist, 170–171, 171*t*
 introduction, 16
 multiple detoxification
 episodes, 177
 outpatient detoxification,
 171–172
 withdrawal symptoms, 16
 diabetes, Type II, 72–73
 Diagnostic Interview Schedule
 (DIS), 153
 diazepam, 121, 173, 177
 diffusion tensor imaging
 (DTI), 29
 disability adjusted life years
 (DALYs), 61
 disarming questions in
 screening, 139–140
 distress behaviour, 116
 distribution of alcohol, 25
 disulfiram, 33, 198,
 199–202, 208
 disulfiram-ethanol reaction
 (DER), 200
 divorce concerns, 53, 55
 dizygotic twin studies, 43
 DNA sequences, 45
 domestic abuse/violence,
 5–6, 137
 dopamine levels, 31–33, 201
 dopaminergic reward
 mesolimbic system, 117
 dopaminergic system, 108
 dose-response relationship,
 64
 Drinker Inventory of
 Consequences
 (DrInC), 163
 drinking history
 drink-related problems, 157
 evolution of, 157
 overview, 157–160
 pressures and
 circumstances, 158
 typical heavy-drinking day,
 158–159
 drinking patterns, 236
 drinking problems. *see also*
 binge drinking; biological
 factors and drinking
 problems; children and
 family-related drinking
 problems; family-related
 drinking problems;
 partner problems and
 drinking; physical
 complications of drinking
 alcohol, as drug, 2
 alcohol-related problems, 2
 background to
 understanding, 1–2
 causes, 2
 defined, 1, 5–6
 high-risk drinking
 categories, 8–10
 introduction, 1
 low-risk drinking, 6–8, 7*t*
 perspective on, 6–8
 range of, 21
 religious/spiritual
 understanding of, 228–230
 social drinking, 41
 subjective awareness of,
 18–19
 unconsciousness and,
 65–66
 work and family-related,
 57–58
 drinking problems, causes
 alcohol availability, 38–39*t*,
 39*t*,
 biological factors, 42–46
 economic factors,
 40–41
 overview, 38
 “self-medication,” 46–47
 values and norms, 41–42
 drinking problems, social
 complications
 crime and, 58–59
 cultural meaning of, 249
 drinking surround
 assessment, 51
 family-related, 52–57, 56*t*
 financial/housing
 instability, 59
 overview, 49
 personal resources and, 52
 pinpointing complications,
 49–50
 select vs. selected, 51–52
 work and education, 57–58
 drinking repertoire, 161
 drinking surround
 assessment, 51
 drug use and alcohol. *see also*
 cocaine use
 amphetamine use, 113,
 119, 125
 benzodiazepine, 121–122,
 122*t*
 cannabis, 112, 113, 114, 115,
 119–120, 123
 club drugs, 123
 diagnosis and screening, 125
 heroin use, 120, 125
 illicit drug use, 30
 ketamine, 34, 123
 nicotine, 117–118
 non-medicinal prescription
 drug use, 123–124
 opioid drug use, 113,
 120–121
 overview, 113*t*, 112–113
 polydrug use, 113–116,
 practical implications, 124*t*,
 124–125
 responsibility for
 prevention, 125
 stimulants, 118–119
 training and service
 organizations and,
 124–125
 treatment goals, 126
 two-way vigilance, 126
 Z-drugs (e.g. zolpidem,
 zopiclone), 123
 drunkalogues in AA, 217
 drunkenness, 42, 49, 58, 77
 DSM-5 criteria, 162
 dual-drinking partnerships,
 54–55
 dually diagnosed, defined, 89
 easy does it, but do it, 221
 eating disorders, 108–109
 e-cigarettes, 118
 education and family-related
 drinking problems, 57–58
 education during
 childhood, 156
 electroencephalography
 (EEG), 30
 Emergency Room treatment,
 135, 138, 147
 empathic style in BMI
 intervention, 149
 en bloc variety of blackouts, 96
 endocrine disorders, 72
 epigenetics, 45
 epilepsy, 78, 140, 177
 episodic heavy drinking, 67
An Essay, Medical,
Philosophical and
Chemical, on Drunkenness
and Its Effects on the
Human Body (Trotter), 15

		Index	261
ethyl alcohol (ethanol), 23, 42, 64, 200	functional MR imaging (fMRI), 29, 30, 81	head injury, 95	
European Court of Justice, 40	GABA-benzodiazepine receptor, 29, 32, 34, 35, 44–45	heart failure, 27	
European Monitoring Centre for Drugs and Drug Addiction, 114	GABAergic neuron, 33, 82, 104	heightened suggestibility, 94	
evidence of dependence, 160–162	gabapentin, 124, 206–207	<i>Helicobacter pylori</i> infection, 72	
excretion of alcohol, 25–27	gamma-aminobutyric acid (GABA), 31	help-seeking by patients, 164–165	
exposure therapy, 105	gamma-glutamyl transferase (GGT), 240	help-seeking pathway, trajectory, 131, 134	
extrahepatic alcohol metabolism, 27	gamma-hydroxybutyrate (GHB), 123	hepatic alcohol metabolism, 26–27	
faith-based treatment, 230	gastric carcinoma, 79	hepatic coma, 179	
family history in assessment, 155–156	gastritis, 72, 115	hepatic encephalopathy, 82, 83	
family-related drinking problems. <i>see also</i> children and family-related drinking problems	gastroenterological disorders, 69–74	hepatitis, alcoholic	
children and, 55–57, 56 <i>t</i>	gastrointestinal disorder, 140	hepatitis B, 62, 70	
couple/family therapies, 195–196	gastrointestinal tract, 28	hepatitis C, 62, 70, 71, 74, 114	
drinking traditions, 42	gender differences in drinking, 20, 25, 42, 70, 90	overview, 70	
linkage studies, 43, 46	gene makeup, 43	risk-taking behaviours and, 114	
overview, 52–57, 56 <i>t</i>	generalized (<i>grand mal</i>) seizures, 17	testing for, 125	
partner as problem, 52–55	General Lifestyle Survey, 8	hepatology clinics, 138	
Fast Alcohol Screening Test (FAST), 145	general psychiatry/mental health services, 139	heroin use, 120, 125	
fatty liver disease, 69, 70	genetics and drinking problems, 43–44	hidden agendas in patients, 252–253	
fear reactions, 93	genome-wide association studies (GWAS), 44	‘high-risk’ behaviours, 106	
feedback in BMI intervention, 149	geriatric care settings, 138–139	high-risk drinking categories, 8–10	
fertility concerns, 73	GGT lab test, 145	Hinduism, 228	
fetal alcohol spectrum disorders (FASD), 64, 83–85	glutamate, 31, 32, 34–35, glutamatergic <i>N</i> -methyl-D-aspartic acid receptor, 30, 204	history-taking in assessment of treatment, 153–154	
fetal alcohol syndrome (FAS), 84	Gosset, William Sealy, 163	HIV infection, 74, 114, 125	
fibrosis of liver, 70	gout, 73–74	‘holiday heart syndrome’, 28, 67	
15-minute assessment, 165	greyouts, 96	homelessness, 59	
finances/housing of patient, 156	group insight-oriented psychotherapy, 197	homemade alcoholic beverages, 61	
financial instability and drinking problems, 59	Group Of Drunks (G.O.D.), 222	hour-by-hour time-tabling, 159	
5HT3 receptor, 45	group therapy, 135, 197–198, 225	housing instability and drinking problems, 59	
fizzy drinks, 25	haematological effects, 76	hyper-arousal, 106	
forensic history of patient, 156	haemorrhagic stroke, 67, 82	hyperglutamatergic state, 96	
formal history in assessments, 154	hallucinations, 17, 93, 95	hyperlipidaemia, 74	
FRAMES mnemonic, 149, 150 <i>t</i>	harmful drinking, 1, 9–10, 11 <i>t</i> –12 <i>t</i> , 198	hypertension, 67	
Frank, Jerome, 221	hazardous drinking, 1, 8, 9	hyperthermia, 179	
Freudian theory, 139	HDL levels, 68	hyperuricaemia from beer, 73	
friendships of patient, 156		hypoglycaemia, 28, 73, 82	
Fuller, Richard, 200		hypomagnesaemia, 80	
		hypomania, 103, 104	
		hypotension, 29, 38	
		hypothermia, 28–29	
		hypothyroidism, 85	
		ibuprofen, 115	
		ICD-10 criteria, 162	

262	Index
illicit drug use, 30	screening and case-finding, 141–144
IMAGEN study, 45	sensitivity and specificity of, 141–142
immune system disorders, 74	L-alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA), 35
impulsive behaviour, 103, 116	larynx cancer, 66
individual behavioural analysis, 238–239	leisure time of patient, 156
inpatient alcohol unit, 5	LifeRing Secular Recovery, 225
inpatient detoxification checklist, 170–171, 171 <i>t</i>	Lincoln, Abraham, 219
insight-oriented psychotherapy, 197	The Links organization, 216
International Agency for Research on Cancer, 66	lithium treatment, 104
International Classification of Diseases, 9	liver cancer, 61, 66
international 'recovery movement,' 252	liver damage/disease
intestinal symptoms, 72	alcoholic liver disease, 64
intoxication effects, 161	chronic myopathy, 75
iron deficiency, 76	cirrhosis of liver, 61, 64, 69–71
ischaemic stroke, 67	diagnostic confusion, 95
Islam, 228, 229, 231	hepatic encephalopathy, 82, 83
Islets of Langerhans, 72	overview, 46, 69 <i>t</i> , 69–70
isopropyl alcohol (isopropanol), 23	liver function tests, 143
itching, 17	lorazepam, 121, 177
jaundice (obstructive jaundice), 70	lower-level monitoring, 189
J-shaped curve, 66	low-risk drinking, 6–8, 7 <i>t</i>
Judaism, 231	macrocytosis, 76
Judeo-Christian understanding of drunkenness, 228	magnetic resonance (MR), 29
kainate (glutamate) receptor, 35	magnetic resonance spectroscopy (MRS), 30
keep it simple, stupid (KISS), 221	magnetoencephalography (MEG), 30
ketamine, 34, 123	Mainz Alcohol Withdrawal Scale, 174
kidney concerns, 28	major depressive disorder, 101, 102, 106
Korsakoff's syndrome, 80–81	Mallory-Weiss syndrome, 72
laboratory tests	mammillo-thalamic tract, 81
blood alcohol concentrations, 143–144	Marchiafava-Bignami disease, 83
carbohydrate-deficient (desialylated) transferrin, 143	marital disharmony as complication, 49–50
for heavy drinking, 142–144	divorce, 53, 55
liver function tests, 143	hidden agendas in patients, 252–253
mean corpuscular volume, 142–143	risk of, 41
other biomarkers, 144	treatment goals, 245–246
overall judgment, 144	Martensen-Larsen, Oluf, 199
overview, 141	MCV lab test, 145
	mean corpuscular volume (MCV), 142–143, 240
	measured electrical activity (EEG, MEG), 29
	medical clues, 140–141
	medically assisted withdrawal, 5
	medical management in non-specialty treatment, 150–151
	medical negligence, 253–254
	megaloblastic anaemia, 76
	memory disorder, 79
	Mendelian randomisation approach, 68
	mental disorders. <i>see</i> behavioural changes/disorders; psychiatric disorders
	'messy' treatment, 134
	metabolic acidosis, 73
	metabolic disorders, 72, 73
	metabolization of alcohol, 25–27, 39, 44
	metabotropic glutamate receptor subtype 5 (mGluR5) antagonism, 204
	methadone maintenance, 120
	methyl alcohol (methanol), 23, 66
	Michigan Alcoholism Screening Test (MAST), 145
	microsomal ethanol-oxidizing system (MEOS), 27, 72
	mild alcohol use disorder, 198
	millimolar concentration (mmol), 24
	mindfulness training, 197
	minimum unit pricing, 40
	mixed affective illnesses, 103–104
	moderate drinking goals, 234
	Moderation Management (MM), 225
	monozygotic twin studies, 43
	mood and behaviour influences, 159, 161
	mood disturbance/disorders, 17, 89
	mood management, 193
	mortality concerns/rates
	alcohol consumption and, 61
	delirium tremens, 94
	meta-analysis of studies, 103
	older adult drug use, 116
	religion and spiritual values, 230–231

	Index	263
respiratory depression and death, 66	alcohol-related physical illness, 236	intervention within, 148–151
motivational enhancement therapy (MET), 192–193	behavioural treatment protocols, 239	introduction, 2
motivational interviewing, 191–193	capacity for self-control, 236	medical management, 150–151
motivation of patient, 156, 187–188, 247	circumstances and company considerations, 238	overview, 136
mouth cancer, 66	competing activities, 238	primary care settings, 138
multiple detoxification episodes, 177	considerations with, 236–237	provision of information, 148
multivitamin therapy, 82	consistency with, 240	schools/colleges/universities, 138
muscle cramps, 17	co-occurring addictive/psychiatric disorders, 236	screening and case-finding, 139–144
mutual help organizations, 216, 225	degree of dependence, 234	screening and intervention, 136–137
myocardial infarctions, 41	drinking patterns, 236	settings of drinking prevalence, 137 <i>t</i> , 137
myopathy, acute, 74–75	drinking speed, 238	sexual health clinics, 138
myopathy, chronic, 75	goals for, 237	summary, 151
	individual behavioural analysis, 238–239	triage in, 146–148
nalmefene, 198, 203–204, 240	initial abstinence interval, 237	workplace setting, 137–138
naltrexone, 201, 202–203, 205, 208	limiting beverage intake, 238	non-steroidal anti-inflammatory drug (NSAID), 115
Narcotics Anonymous (NA), 216	limiting types of beverages, 237	novel psychoactive substances (NPS), 123
National Comorbidity Survey, 91	medication use with, 239–240	nucleus accumbens, 31, 33
National Epidemiologic Survey on Alcohol Problems and Related Conditions (NESARC), 90, 91	motivations with drinking, 238	‘number needed to treat’ (NNT), 202, 204
National Health Service (UK), 230	overview, 234	obesity concerns, 108–109
National Institute for Health and Clinical Excellence, 173, 207	partner involvement, 240	occupational delusions, 94
National Institute of Alcohol Abuse and Alcoholism, 200	realistic preference, 235	occupational history, 156
Native American religion, 229–230	risk associations, 239	oesophageal concerns, 66, 71, 72
nausea, 17	sustained controlled drinking, 235 <i>t</i> , 235	older adult drug use, 116
neurobiological vulnerabilities, 45–46	techniques for control in, 237–239	opioid drug use, 113, 120–121
neuroimaging, 29–30, 43, 45, 82	non-accidental injury, 56	opioid (mu) receptors, 31, 33
neurological disorders, 77–83	non-dependent alcohol drinkers, 16	OPRM1 gene, 45
neurotic depression, 100	non-fatal suicide behaviour, 103	osteoporosis, 75
neurotransmitters, 31, 44–45	non-judgmental listening, 197	outpatient detoxification, 171–172
neutropaenia, 76	non-medicinal prescription drug use, 123–124	over-the-counter (OTC) medicines, 115
nicotine and alcohol, 117–118	non-specialty treatment	oxazepam, 121
nicotine replacement therapy (NRT), 118	brief motivational intervention, 148–149, 150 <i>t</i>	Paddington Alcohol Test (PAT), 145
nicotinic receptors, 31	criminal justice setting, 137	palpitations, 67
non-abstinence treatment acceptable outcomes, 241	Emergency Room setting, 138	pancreatitis, acute, 64, 71
	general psychiatry/mental health services, 139	pancreatitis, chronic, 64, 71–72, 115
	geriatric care settings, 138–139	paracetamol (acetaminophen), 115
	hepatology clinics, 138	paranoid delusions, 93–94
		parental drinking problems, 55–57

Cambridge University Press

978-1-107-51952-7 - Edwards' Treatment of Drinking Problems: A Guide for the Helping Professions

Sixth Edition Keith Humphreys and Anne Lingford-Hughes

Index

[More information](#)

264

Index

- parental psychopathology, 57
- partner problems and drinking
dual-drinking partnerships,
54–55
impact of, 53–54
individual histories, 53
overview, 52–53, 64–65, 65*t*
- pathoplastic influences, 13
- patient challenges for
clinicians, 247–253, 250*t*
- pellagra encephalopathy, 81–82
- peptic ulceration, 72
- peripheral neuropathy, 78
- personal beliefs about
drinking, 42
- personal finances and
drinking, 41
- personal history in
assessment, 156
- personality disorder, 107
Persuasion and Healing
(Frank), 221
- pharmacology of alcohol, 23,
24*t*, 31
- pharmacotherapy. *see also*
benzodiazepine use
acamprosate, 198, 201,
204–205, 208
alcohol dependence, 107
anxiety disorder and,
207–208
baclofen, 206
bipolar disorder, 208
chlordiazepoxide, 121,
173, 180
depression and, 99–101, 207
diazepam, 121, 173, 177
disulfiram, 33, 198,
199–202, 208
nalmefene, 198,
203–204, 240
naltrexone, 201, 202–203,
205, 208
other pharmacotherapies,
206–207
oxazepam, 121
pregabalin and gabapentin,
206–207
with psychiatric
comorbidities, 207
regulation of brain
functioning, 202–205
schizophrenia, 208
specialist treatment, 198–199
temazepam, 121
topiramate, 206
- pharynx cancer, 66
- phenethylamines, 123
- phenothiazines, 179
- phobic anxiety symptoms, 105
- physical abuse in
childhood, 106
- physical complications of
drinking
accidents and trauma from
alcohol, 77
acute alcohol intoxication
and coma, 65–66
alertness over, 85
arrhythmias, 67
cancers, 66
cardiomyopathy, 68–69
cardiovascular disease,
28, 66
coronary heart disease, 68
fetal alcohol spectrum
disorders, 64, 83–85
gastroenterological
disorders, 69–74
haematological effects, 76
hypertension, 67
immune system
disorders, 74
impact of, 61–64, 62*t*
muscle, skin and bone
disease, 74–75
neurological disorders,
77–83
non-abstinence
treatment, 236
overview, 61
patient concern over, 63
respiratory disease, 75–76
stroke, 27, 67–68
surgical complications, 77
- physical disturbances, 94
- physical examination and
investigation, 165
- physical exercise and
absorption, 25
- physical violence in patients,
249–250
- ‘ping-pong’ treatment, 135
- piperazines, 123
- ‘pleasure-reward-motivation’
pathway, 202
- pneumonia, 74, 95
- police support for treatment
plan, 251
- polydrug use, 113–116
- population factors in
drinking, 40
- portal hypertension, 70
- positron emission tomography
(PET), 29, 33, 81
- post-traumatic stress disorder
(PTSD), 106–107, 124,
157, 246
- PREDICT studies, 205
- pregabalin, 124, 206–207
- prescription painkillers, 114
- previous illnesses of
patient, 157
- price of alcohol and
drinking, 40
- primary care settings, 138
- pro-alcohol marketing, 42
- probing and checking by
physician, 159–160
- problem drinking, 1
- prodromal symptoms, 92
- Prohibition period, 38
- Project MATCH, 192, 194, 196
- proof, defined, 25
- provision of information, 148
- pseudo-Cushing’s
syndrome, 73
- pseudo-zero-order of
metabolism, 26
- psoriasis, 75
- psychiatric clues, 140
- psychiatric disorders. *see also*
depression
alcohol-induced disorders,
92–95
alcohol-induced psychotic
disorder, 95–96
alcohol-related brain
damage, 79, 82–83, 97–99
attention deficit
hyperactivity disorder,
107–108
bipolar disorder, 103–104
blackouts, 96–97
co-morbidity, 99
eating disorders and obesity
concerns, 108–109
epidemiology, 89–91, 90*t*,
91*t*
general implications, 109
mental disorders, 62
overview, 89
personality disorder, 107
post-traumatic stress
disorder, 106–107
psychosis and
schizophrenia, 108
suicide and self-harm, 103

	Index	265
psychoactive substance use, 9	sadness feelings, 100	sexual abuse of children, 56, 106
psychodynamic psychotherapy, 197	salience of drinking, 161	sexual health clinics, 138
psychosis, 108	salient alcohol cues, 30	sexual interest, loss of, 100
psychostimulants use/abuse, 108	Salvation Army, 229, 230	sexually transmitted diseases, 74
psychotic symptoms, 100	schizophrenia, 96, 108, 208, 245	Short Alcohol Dependence Data questionnaire, 162
pub crawls, 6	Scotch Whisky Association, 40	single nucleotide polymorphisms (SNPs), 44
questionnaires for measuring dependence, 162	screening and case-finding advantages and disadvantages, 146 <i>t</i>	single photon emission tomography (SPET), 29
questionnaires in screening, 144–145	at-risk persons, 140	situational cues, 19
radiolabeled tracers, 29	common social presentations, 140	skeletal muscles and alcohol, 74–75
rebellious patients, 247–248	disarming questions in, 139–140	skin disorders, 75
reduced cell-mediated immunity, 74	laboratory tests, 141–144	skull radiography, 66
reflective listening, 192	medical clues, 140–141	sleep disturbance, 17
reinstatement after abstinence, 19	non-specialty treatment, 139–144	SMART Recovery mutual help group, 135, 225
relapse, 170, 190, 198	obvious indicators, 141	smoking cessation interventions, 118
relief drinking, 17–18, 19	practical conclusions, 145,	smooth endoplasmic reticulum (SER), 27
religion/spirituality in treatment definitions, 227–228	psychiatric clues, 140	Social Behaviour and Network Therapy (SBNT), 193
individual programmes, 231–232	questionnaires, 144–145	social drinking, 41
moral values in, 230–231	technological aids to, 141	social presentations, 140
overview, 3, 42, 227	Secular Organizations for Sobriety, 225	specialist treatment behavioural self-control training, 194–195
treatment programs based on, 230	seizures, 77–78, 169	cognitive behavioural therapy, 193
understanding drinking problems, 228–230	self-control issues, 28	community reinforcement approach, 194
respiration concerns, 28	self-efficacy, 149, 192	coping and social skills training, 193–194
respiratory depression and death, 66	self-harm risks with patients, 253	couple/family therapies, 195–196
respiratory disease, 75–76	“self-medication” as drinking problem, 46–47	cue exposure, 195
respiratory infections, 74	sensible drinking guidelines, 1	effective treatments, 190–191, 191 <i>t</i>
respiratory tract infection, 75–76	sensitivity to sound (hyperacusis), 17	group therapy, 197–198
responsibility in BMI intervention, 149	Serenity Prayer, 218	mindfulness training, 197
restlessness/agitation, 94	serotonin reuptake inhibitors (SSRIs), 207	motivational interviewing, 191–193
‘revolving-door’ patients, 135	serotonin transporter, 45	overview, 3, 10, 190
reward system in alcohol dependence, 30, 31–33	serum alanine aminotransferase (ALT), 143	pharmacotherapy, 198–199
ringing in the ears (tinnitus), 17	serum aspartate aminotransferase (AST), 143	psychodynamic psychotherapy, 197
risk-taking behaviours, 114, 239, 253	serum concentrations, 24	real-world delivery of, 208
romantic relationships, 156	serum gamma-glutamyl transferase (GGT), 143	resistance, 147
Royal Colleges of Physicians, Psychiatrists and General Practitioners, 6	setbacks and challenges in treatment, 3	transfer to, 148
ruminating on alcohol, 19	severe alcohol dependence, 5, 19	
	Severity of Alcohol Dependence Questionnaire, 162	

- spirituality. *see* religion/
spirituality in treatment
- status epilepticus, 78
- stepped-care concept, 147
- stimulants and alcohol,
118–119
- stomach wash-out, 66
- stress and alcohol dependence,
41, 53, 103
- stroke, 27, 67–68
- Structured Clinical Interview
for DSM-V, 153
- subarachnoid haemorrhage,
82, 98
- subjective awareness and
compulsion to drink, 161
- substance use disorder, 90, 108
- suicide and self-harm, 103
- supraventricular tachycardia
(SVT), 28
- surgical complications, 77
- sustained controlled drinking,
235*t*, 235
- sweating, 17
- symbolic significance of
alcohol, 23
- synaptic plasticity, 35
- syndrome, defined, 10, 19–20
- synthetic cannabinoids, 123
- synthetic cathinones, 123
- T-ACE questionnaire, 145
- taxes on alcohol and
drinking, 40
- Teen Challenge, 229
- temazepam, 121
- Temperance Movement,
219, 229
- therapeutic relationship in
treatment
characteristics of, 185*t*, 185
common goal of, 186
empathy, caring, and
trust, 186
ending of, 188–189
as motivation source,
187–188
overview, 3, 184
responsibility for behaviour,
186–187
- thiamine (vitamin B1)
deficiency, 68, 79,
83, 176
- thiamine (vitamin B1)
treatment, 80
- thrombocytopaenia, 76
- time element of alcohol
dependence, 20
- tobacco-related disease, 117
- tolerance
alcohol, as drug, 32, 34–35
GABA and, 32, 34, 35
glutamate, 32, 34–35,
increases/decreases in, 161
withdrawal symptoms and,
19, 35
- topiramate, 206
- training and service
organizations, 124–125
- transient hallucinatory
experience, 92
- traumatic memories, 106
- treatment. *see also* assessment
of patients; non-
abstinence treatment;
non-specialty treatment;
religion/spirituality in
treatment; screening
and case-finding;
specialist treatment;
therapeutic relationship in
treatment
assessment, 2, 166–167
case-finding and
intervention, 2
delirium tremens, 177–179,
178*t*, 244
faith-based, 230
goals in, 166
help-seeking pathway,
131, 134
introduction, 131–133
'messy' treatment, 134
neurotransmitter pathways
and, 44–45
other than abstinence, 3
physical complications of
drinking, 85
relevance of understanding
to, 21
religion/spirituality in, 3
setbacks and challenges, 3
settings and roles, 2
therapeutic relationship, 3
withdrawal states, 2–3
treatment setbacks/challenges
aggressive/violent patients,
249–251, 250*t*,
ambitious/unambitious
goals, 245–247
common methods of,
244–247
- drinking emphasis concerns,
244–245
- hidden agendas in patients,
252–253
- indulgence *vs.* demands, 247
- managing setbacks, 254*t*
- medical negligence, 253–254
- overview, 243*t*, 243–244
- patient challenges for
clinicians, 247–253, 250*t*
- patients with varying
cultural backgrounds,
248–249
- police support for treatment
plan, 251
- rebellious patients, 247–248
- VIP patients, 251–252
- tremor, 17, 19, 93
- triage in non-specialty setting,
146–148
- tricyclic antidepressants, 201
- Trotter, Thomas, 15–16
- t-test, 163–164
- tuberculosis, 74
- TWEAK questionnaire, 145
- twelve-step facilitation therapy,
196–197, 220*t*, 224–225
- 12-step facilitation (TSF), 193
- Type II diabetes, 72–73
- typical heavy-drinking day,
158–159
- UK Alcohol Treatment
Trial, 196
- unconsciousness and drinking,
65–66
- United Kingdom Alcohol
Treatment Trial
(UKATT), 192
- U.S. Food and Drug
Administration, 202
- U.S. National Comorbidity
Survey, 89, 90*t*
- U.S. National Institute on
Alcohol Abuse and
Alcoholism, 150
- U.S. National Longitudinal
Alcohol Epidemiologic
Survey, 8
- varenicline treatment, 118
- ventral striatum (nucleus
accumbens), 30
- ventral tegmental area
(VTA), 30
- ventricular arrhythmias, 67

		Index	267
ventricular tachyarrhythmia, 69	anxiety with depression, 104–105	medication regimen for, 169, 171, 172–174, 179	
ventromedial prefrontal cortex, 31	avoidance of, 161	monitoring during, 174–175	
victims of crime, 59–59	avoidance of through drinking, 17–18	non-alcohol drugs, 180–181	
villae, defined, 25	case history, 179–180	older patients, 174	
VIP patients in treatment, 251–252	check-list for management of, 170–172	overview, 16–17, 169	
vitamins for withdrawal, 175–176	clinical management of, 171–172	pregnant patients, 174	
	clinical teamwork, 170	seizures, 176–177	
waking events, typical day, 159	in context, 170	seizures from, 77–78	
Washington George, 219	delirium tremens, 94, 169, 171, 177–179	significance of, 169–170	
the Washingtonians, 219–220	dependence in the absence of, 19–20	summary, 181	
‘weakness of the will,’ 20	detoxification, 16	time element and, 20	
Wernicke-Korsakoff syndrome, 79, 176	drinking history, 161	timing of, 172	
Wernicke’s encephalopathy, 79–80, 81, 175, 176	environmental support, 172	vitamins and, 175–176, 179	
White, William, 219	fluids and electrolytes, 179	Women for Sobriety, 216, 225	
wine consumption, 6, 40, 41	GABA and, 32, 34	work and family-related drinking problems, 57–58	
withdrawal states/symptoms	glutamate, 32, 34–35	workplace setting, 137–138	
alcohol, as drug, 32, 34–35	in-patient detoxification checklist, 171 <i>t</i>	World Cancer Research Fund, 66	
alternative medications, 175	introduction, 2–3	World Health Organization (WHO), 6, 113, 144	
	life support, 179		
	medically assisted withdrawal, 5	youth culture, 42	
		Z-drugs (e.g. zolpidem, zopiclone), 123	